A study utilizing the DNA methyltransferase (DNMT) inhibitor decitabine to treat PC3 prostate cancer cells resulted in the demethylation of the DKK3 promoter, leading to elevated DKK3 expression and the inhibition of TGF-β/Smad-dependent transcriptional activity. The gene discussed is DKK3; the disease is prostate cancer.